Do analysts rate NCEL or BRTX?

NLS Pharmaceutics presently has a consensus price target of $23.00, indicating a potential upside of 596.97%. Given NLS Pharmaceutics' stronger consensus rating and higher probable upside, equities research analysts plainly believe NLS Pharmaceutics is more favorable than Biorestorative Therapies. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score NLS Pharmaceutics 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Biorestorative Therapies 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has better valuation and earnings, NCEL or BRTX?

NLS Pharmaceutics has higher earnings, but lower revenue than Biorestorative Therapies. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio NLS Pharmaceutics N/A N/A -$8.30M N/A N/A Biorestorative Therapies $360K 10.24 -$14.24M -$1.07 N/A

Which has stronger earnings & valuation, PMVP or NCEL?

Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio PMV Pharmaceuticals N/A N/A -$77.74M -$1.42 N/A NLS Pharmaceutics N/A N/A -$8.30M N/A N/A

Is PMVP or NCEL more profitable?

NLS Pharmaceutics' return on equity of 0.00% beat PMV Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets PMV Pharmaceuticals N/A -78.11% -70.13% NLS Pharmaceutics N/A N/A N/A

Which has better valuation & earnings, RNTX or NCEL?

Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Rein Therapeutics N/A N/A -$49.87M -$1.72 N/A NLS Pharmaceutics N/A N/A -$8.30M N/A N/A

Is RNTX or NCEL more profitable?

Company Net Margins Return on Equity Return on Assets Rein Therapeutics N/A N/A -63.69% NLS Pharmaceutics N/A N/A N/A

Which has better valuation and earnings, NCEL or PLRX?

NLS Pharmaceutics has higher earnings, but lower revenue than Pliant Therapeutics. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio NLS Pharmaceutics N/A N/A -$8.30M N/A N/A Pliant Therapeutics $1.58M 45.85 -$149.34M -$1.49 N/A

Is NCEL or PLRX more profitable?

NLS Pharmaceutics' return on equity of 0.00% beat Pliant Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets NLS Pharmaceutics N/A N/A N/A Pliant Therapeutics N/A -52.17% -40.46%

Do analysts rate INMB or NCEL?

NLS Pharmaceutics has a consensus target price of $23.00, indicating a potential upside of 596.97%. Given NLS Pharmaceutics' higher possible upside, analysts clearly believe NLS Pharmaceutics is more favorable than INmune Bio. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score INmune Bio 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 1 Strong Buy rating(s) 2.50 NLS Pharmaceutics 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Which has higher valuation and earnings, INMB or NCEL?

NLS Pharmaceutics has lower revenue, but higher earnings than INmune Bio. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio INmune Bio $50K 1,232.10 -$45.93M -$0.67 N/A NLS Pharmaceutics N/A N/A -$8.30M N/A N/A

Is INMB or NCEL more profitable?

NLS Pharmaceutics' return on equity of 0.00% beat INmune Bio's return on equity. Company Net Margins Return on Equity Return on Assets INmune Bio N/A -82.87% -62.23% NLS Pharmaceutics N/A N/A N/A

NLS Pharmaceutics (NCEL) Competitors

$3.30 -0.08 (-2.37%)

As of 09/11/2026 02:44 PM Eastern

Compare

NCEL vs. BRTX, PMVP, RNTX, PLRX, and INMB

Should you buy NLS Pharmaceutics stock or one of its competitors? NLS Pharmaceutics's main competitors and comparable companies include Biorestorative Therapies (BRTX), PMV Pharmaceuticals (PMVP), Rein Therapeutics (RNTX), Pliant Therapeutics (PLRX), and INmune Bio (INMB). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does NLS Pharmaceutics compare to Biorestorative Therapies?

NLS Pharmaceutics (NASDAQ:NCEL) and Biorestorative Therapies (NASDAQ:BRTX) are both small-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their dividends, earnings, risk, valuation, analyst recommendations, profitability, institutional ownership and media sentiment.

NLS Pharmaceutics presently has a consensus price target of $23.00, indicating a potential upside of 596.97%. Given NLS Pharmaceutics' stronger consensus rating and higher probable upside, equities research analysts plainly believe NLS Pharmaceutics is more favorable than Biorestorative Therapies.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
NLS Pharmaceutics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Biorestorative Therapies	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

NLS Pharmaceutics has a beta of 0.94, indicating that its stock price is 6% less volatile than the broader market. Comparatively, Biorestorative Therapies has a beta of 0.83, indicating that its stock price is 17% less volatile than the broader market.

In the previous week, Biorestorative Therapies had 1 more articles in the media than NLS Pharmaceutics. MarketBeat recorded 3 mentions for Biorestorative Therapies and 2 mentions for NLS Pharmaceutics. NLS Pharmaceutics' average media sentiment score of 1.44 beat Biorestorative Therapies' score of 0.96 indicating that NLS Pharmaceutics is being referred to more favorably in the media.

Company	Overall Sentiment
NLS Pharmaceutics	Positive
Biorestorative Therapies	Positive

NLS Pharmaceutics has a net margin of 0.00% compared to Biorestorative Therapies' net margin of -3,088.27%. NLS Pharmaceutics' return on equity of 0.00% beat Biorestorative Therapies' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
NLS Pharmaceutics	N/A	N/A	N/A
Biorestorative Therapies	-3,088.27%	-508.42%	-230.94%

69.4% of Biorestorative Therapies shares are owned by institutional investors. 16.4% of NLS Pharmaceutics shares are owned by insiders. Comparatively, 13.6% of Biorestorative Therapies shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

NLS Pharmaceutics has higher earnings, but lower revenue than Biorestorative Therapies.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
NLS Pharmaceutics	N/A	N/A	-$8.30M	N/A	N/A
Biorestorative Therapies	$360K	10.24	-$14.24M	-$1.07	N/A

Summary

NLS Pharmaceutics beats Biorestorative Therapies on 10 of the 13 factors compared between the two stocks.

How does NLS Pharmaceutics compare to PMV Pharmaceuticals?

PMV Pharmaceuticals (NASDAQ:PMVP) and NLS Pharmaceutics (NASDAQ:NCEL) are both small-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their institutional ownership, risk, earnings, profitability, analyst recommendations, dividends, valuation and media sentiment.

PMV Pharmaceuticals presently has a consensus target price of $4.33, suggesting a potential upside of 209.52%. NLS Pharmaceutics has a consensus target price of $23.00, suggesting a potential upside of 596.97%. Given NLS Pharmaceutics' higher probable upside, analysts plainly believe NLS Pharmaceutics is more favorable than PMV Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
PMV Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.80
NLS Pharmaceutics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

90.2% of PMV Pharmaceuticals shares are owned by institutional investors. 10.2% of PMV Pharmaceuticals shares are owned by company insiders. Comparatively, 16.4% of NLS Pharmaceutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

In the previous week, PMV Pharmaceuticals had 14 more articles in the media than NLS Pharmaceutics. MarketBeat recorded 16 mentions for PMV Pharmaceuticals and 2 mentions for NLS Pharmaceutics. NLS Pharmaceutics' average media sentiment score of 1.44 beat PMV Pharmaceuticals' score of 0.88 indicating that NLS Pharmaceutics is being referred to more favorably in the news media.

Company	Overall Sentiment
PMV Pharmaceuticals	Positive
NLS Pharmaceutics	Positive

PMV Pharmaceuticals has a beta of 1.37, suggesting that its stock price is 37% more volatile than the broader market. Comparatively, NLS Pharmaceutics has a beta of 0.94, suggesting that its stock price is 6% less volatile than the broader market.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
PMV Pharmaceuticals	N/A	N/A	-$77.74M	-$1.42	N/A
NLS Pharmaceutics	N/A	N/A	-$8.30M	N/A	N/A

NLS Pharmaceutics' return on equity of 0.00% beat PMV Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
PMV Pharmaceuticals	N/A	-78.11%	-70.13%
NLS Pharmaceutics	N/A	N/A	N/A

Summary

PMV Pharmaceuticals and NLS Pharmaceutics tied by winning 6 of the 12 factors compared between the two stocks.

How does NLS Pharmaceutics compare to Rein Therapeutics?

Rein Therapeutics (NASDAQ:RNTX) and NLS Pharmaceutics (NASDAQ:NCEL) are both small-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, dividends, media sentiment, earnings, profitability, analyst recommendations, valuation and risk.

Rein Therapeutics has a beta of 1.37, suggesting that its stock price is 37% more volatile than the broader market. Comparatively, NLS Pharmaceutics has a beta of 0.94, suggesting that its stock price is 6% less volatile than the broader market.

Company	Net Margins	Return on Equity	Return on Assets
Rein Therapeutics	N/A	N/A	-63.69%
NLS Pharmaceutics	N/A	N/A	N/A

90.9% of Rein Therapeutics shares are owned by institutional investors. 1.5% of Rein Therapeutics shares are owned by insiders. Comparatively, 16.4% of NLS Pharmaceutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Rein Therapeutics	N/A	N/A	-$49.87M	-$1.72	N/A
NLS Pharmaceutics	N/A	N/A	-$8.30M	N/A	N/A

In the previous week, Rein Therapeutics had 1 more articles in the media than NLS Pharmaceutics. MarketBeat recorded 3 mentions for Rein Therapeutics and 2 mentions for NLS Pharmaceutics. Rein Therapeutics' average media sentiment score of 1.61 beat NLS Pharmaceutics' score of 1.44 indicating that Rein Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Rein Therapeutics	Very Positive
NLS Pharmaceutics	Positive

Rein Therapeutics currently has a consensus price target of $6.00, suggesting a potential upside of 664.33%. NLS Pharmaceutics has a consensus price target of $23.00, suggesting a potential upside of 596.97%. Given Rein Therapeutics' stronger consensus rating and higher possible upside, equities research analysts clearly believe Rein Therapeutics is more favorable than NLS Pharmaceutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Rein Therapeutics	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
NLS Pharmaceutics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Summary

Rein Therapeutics beats NLS Pharmaceutics on 7 of the 10 factors compared between the two stocks.

How does NLS Pharmaceutics compare to Pliant Therapeutics?

NLS Pharmaceutics (NASDAQ:NCEL) and Pliant Therapeutics (NASDAQ:PLRX) are both small-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, risk, analyst recommendations, valuation, profitability, earnings, dividends and media sentiment.

NLS Pharmaceutics has a beta of 0.94, indicating that its share price is 6% less volatile than the broader market. Comparatively, Pliant Therapeutics has a beta of 1.27, indicating that its share price is 27% more volatile than the broader market.

97.3% of Pliant Therapeutics shares are owned by institutional investors. 16.4% of NLS Pharmaceutics shares are owned by insiders. Comparatively, 8.7% of Pliant Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

NLS Pharmaceutics' return on equity of 0.00% beat Pliant Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
NLS Pharmaceutics	N/A	N/A	N/A
Pliant Therapeutics	N/A	-52.17%	-40.46%

NLS Pharmaceutics currently has a consensus price target of $23.00, suggesting a potential upside of 596.97%. Pliant Therapeutics has a consensus price target of $3.00, suggesting a potential upside of 156.41%. Given NLS Pharmaceutics' stronger consensus rating and higher possible upside, analysts clearly believe NLS Pharmaceutics is more favorable than Pliant Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
NLS Pharmaceutics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Pliant Therapeutics	2 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	1.75

NLS Pharmaceutics has higher earnings, but lower revenue than Pliant Therapeutics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
NLS Pharmaceutics	N/A	N/A	-$8.30M	N/A	N/A
Pliant Therapeutics	$1.58M	45.85	-$149.34M	-$1.49	N/A

In the previous week, Pliant Therapeutics had 1 more articles in the media than NLS Pharmaceutics. MarketBeat recorded 3 mentions for Pliant Therapeutics and 2 mentions for NLS Pharmaceutics. Pliant Therapeutics' average media sentiment score of 1.48 beat NLS Pharmaceutics' score of 1.44 indicating that Pliant Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
NLS Pharmaceutics	Positive
Pliant Therapeutics	Positive

Summary

NLS Pharmaceutics beats Pliant Therapeutics on 6 of the 11 factors compared between the two stocks.

How does NLS Pharmaceutics compare to INmune Bio?

INmune Bio (NASDAQ:INMB) and NLS Pharmaceutics (NASDAQ:NCEL) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their media sentiment, risk, analyst recommendations, profitability, valuation, dividends, institutional ownership and earnings.

12.7% of INmune Bio shares are owned by institutional investors. 21.4% of INmune Bio shares are owned by company insiders. Comparatively, 16.4% of NLS Pharmaceutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

NLS Pharmaceutics' return on equity of 0.00% beat INmune Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
INmune Bio	N/A	-82.87%	-62.23%
NLS Pharmaceutics	N/A	N/A	N/A

NLS Pharmaceutics has a consensus target price of $23.00, indicating a potential upside of 596.97%. Given NLS Pharmaceutics' higher possible upside, analysts clearly believe NLS Pharmaceutics is more favorable than INmune Bio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
INmune Bio	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.50
NLS Pharmaceutics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

INmune Bio has a beta of 0.93, meaning that its stock price is 7% less volatile than the broader market. Comparatively, NLS Pharmaceutics has a beta of 0.94, meaning that its stock price is 6% less volatile than the broader market.

NLS Pharmaceutics has lower revenue, but higher earnings than INmune Bio.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
INmune Bio	$50K	1,232.10	-$45.93M	-$0.67	N/A
NLS Pharmaceutics	N/A	N/A	-$8.30M	N/A	N/A

In the previous week, INmune Bio and INmune Bio both had 2 articles in the media. NLS Pharmaceutics' average media sentiment score of 1.44 beat INmune Bio's score of 0.93 indicating that NLS Pharmaceutics is being referred to more favorably in the news media.

Company	Overall Sentiment
INmune Bio	Positive
NLS Pharmaceutics	Positive

Summary

NLS Pharmaceutics beats INmune Bio on 7 of the 12 factors compared between the two stocks.

Get NLS Pharmaceutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding NCEL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

NCEL vs. The Competition

Export

Metric	NLS Pharmaceutics	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$19.09M	$3.85B	$7.15B	$12.85B
Dividend Yield	N/A	3.65%	2.57%	11.17%
P/E Ratio	N/A	14.18	274.94	25.36
Price / Sales	N/A	1,374.99	686.57	116.78
Price / Cash	N/A	106.50	76.65	51.52
Price / Book	2.08	15.12	10.33	6.20
Net Income	-$8.30M	-$22.86M	$3.50B	$358.50M
7 Day Performance	-1.49%	-4.34%	-3.32%	-2.35%
1 Month Performance	-8.33%	0.54%	-0.53%	-3.23%
1 Year Performance	-84.65%	40.74%	23.51%	8.79%

NLS Pharmaceutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
NCEL NLS Pharmaceutics	2.8725 of 5 stars	$3.30 -2.4%	$23.00 +597.0%	-84.7%	$19.09M	N/A	N/A	6	Short Interest Decrease Gap Down
BRTX Biorestorative Therapies	1.1063 of 5 stars	$2.70 -3.8%	N/A	-91.3%	$74.44M	$360K	N/A	7	Upcoming Earnings Short Interest Decrease
PMVP PMV Pharmaceuticals	3.3197 of 5 stars	$1.36 +1.1%	$4.33 +219.8%	+13.8%	$72.44M	N/A	N/A	50	Analyst Downgrade Analyst Revision
RNTX Rein Therapeutics	3.4419 of 5 stars	$0.84 -3.1%	$6.00 +617.7%	-34.0%	$72.12M	N/A	N/A	9	Positive News Gap Up
PLRX Pliant Therapeutics	1.932 of 5 stars	$1.16 +1.8%	$3.00 +159.7%	-26.4%	$71.52M	N/A	N/A	90	Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:NCEL) was last updated on 9/13/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

NLS Pharmaceutics (NCEL) Competitors

NCEL vs. BRTX, PMVP, RNTX, PLRX, and INMB

How does NLS Pharmaceutics compare to Biorestorative Therapies?

Summary

How does NLS Pharmaceutics compare to PMV Pharmaceuticals?

Summary

How does NLS Pharmaceutics compare to Rein Therapeutics?

Summary

How does NLS Pharmaceutics compare to Pliant Therapeutics?

Summary

How does NLS Pharmaceutics compare to INmune Bio?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

NCEL vs. The Competition

NLS Pharmaceutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

NLS Pharmaceutics (NCEL) Competitors

NCEL vs. BRTX, PMVP, RNTX, PLRX, and INMB

How does NLS Pharmaceutics compare to Biorestorative Therapies?

Do analysts rate NCEL or BRTX?

Which has more volatility and risk, NCEL or BRTX?

Does the media refer more to NCEL or BRTX?

Is NCEL or BRTX more profitable?

Do insiders and institutionals hold more shares of NCEL or BRTX?

Which has better valuation and earnings, NCEL or BRTX?

Summary

How does NLS Pharmaceutics compare to PMV Pharmaceuticals?

Do analysts rate PMVP or NCEL?

Do insiders & institutionals hold more shares of PMVP or NCEL?

Does the media prefer PMVP or NCEL?

Which has more volatility & risk, PMVP or NCEL?

Which has stronger earnings & valuation, PMVP or NCEL?

Is PMVP or NCEL more profitable?

Summary

How does NLS Pharmaceutics compare to Rein Therapeutics?

Which has more risk and volatility, RNTX or NCEL?

Is RNTX or NCEL more profitable?

Do insiders and institutionals hold more shares of RNTX or NCEL?

Which has better valuation & earnings, RNTX or NCEL?

Does the media favor RNTX or NCEL?

Do analysts rate RNTX or NCEL?

Summary

How does NLS Pharmaceutics compare to Pliant Therapeutics?

Which has more risk and volatility, NCEL or PLRX?

Do insiders & institutionals hold more shares of NCEL or PLRX?

Is NCEL or PLRX more profitable?

Do analysts rate NCEL or PLRX?

Which has better valuation and earnings, NCEL or PLRX?

Does the media favor NCEL or PLRX?

Summary

How does NLS Pharmaceutics compare to INmune Bio?

Do insiders & institutionals hold more shares of INMB or NCEL?

Is INMB or NCEL more profitable?

Do analysts rate INMB or NCEL?

Which has more risk and volatility, INMB or NCEL?

Which has higher valuation and earnings, INMB or NCEL?

Does the media prefer INMB or NCEL?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

NCEL vs. The Competition

NLS Pharmaceutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools